Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

163.10 +1.92 (+1.19%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

41 42 Next >

Novartis Extends Breakout As Three Key Drivers Lead To A Beat-And-Raise ↗

April 25, 2023

Novartis stock popped on its guidance boost early Tuesday after the company beat first-quarter expectations.

Via Investor's Business Daily

3 Top Biotech Stocks Defying the Bear Market ↗

April 25, 2023

All three companies have therapies with strong sales potential.

Via The Motley Fool

Why Novartis Stock Is Trading Higher Today ↗

April 25, 2023

Via Benzinga

Earnings Preview: Novartis ↗

April 24, 2023

Via Benzinga

Novartis Says Relapsing Multiple Sclerosis Patients Remained Free From Disease Progression For Up Five Years With Kesimpta Treatment ↗

April 20, 2023

Via Benzinga

Why Shares of Legend Biotech Jumped Wednesday ↗

April 19, 2023

A leaked abstract on a phase 3 trial for the company's multiple myeloma drug Carvykti gave the stock a jolt.

Via The Motley Fool

New York Rep. Daniel Goldman Bought Over $50K Worth of Novartis Stock: Here's What You Should Know ↗

April 18, 2023

Via Benzinga

Novartis Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

April 13, 2023

Via Benzinga

FDA Approves Pharming's Immune Disorder Drug, As First APDS Therapy ↗

March 27, 2023

Via Benzinga

How Is The Market Feeling About Novartis? ↗

March 21, 2023

Via Benzinga

2 Best Biotech Stocks to Buy for the Long Haul ↗

April 17, 2023

These two are among the largest pharma companies in the world.

Via The Motley Fool

7 Sorry Pharma Stocks to Sell in April Before It’s Too Late ↗

April 16, 2023

You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards.

Via InvestorPlace

Relay Therapeutics' Stock Price Premium Vs Peers Is Justified By Its Platform Technology, Analyst Says ↗

April 13, 2023

Via Benzinga

Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer? ↗

April 13, 2023

In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or...

Via Benzinga

Trillions In Biotech Stock Gains Trace Back To This Financier ↗

April 13, 2023

Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider.

Via Investor's Business Daily

Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move ↗

April 10, 2023

Via Benzinga

Top-Notch Biotech TG Therapeutics Logs 'Solid Jump' In Sales; Shares Rocket ↗

April 10, 2023

Shares are closing in on a buy point out of a consolidation.

Via Investor's Business Daily

Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity? ↗

April 10, 2023

The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.

Via Benzinga

6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative' ↗

April 07, 2023

Rocket Pharma (NASDAQ: RCKT) CEO Gaurav Shah is on a mission to "change the narrative" when it comes to rare diseases.

Via Benzinga

7 Very Undervalued Penny Stocks to Buy in April 2023 ↗

April 06, 2023

Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option.

Via InvestorPlace

The Byzantine Adderall Shortage Puts Teva And Others In The Hot Seat ↗

April 05, 2023

Millions of people are scrambling to get their ADHD medication. Here's why.

Via Investor's Business Daily

Stock Market Rallies On Micron, Alibaba, Lululemon, Ebbing Bank Fears: Weekly Review ↗

March 31, 2023

The stock market rallied on ebbing bank fears and positive news from Micron, Alibaba and Lululemon Athletica.

Via Investor's Business Daily

What Bear Market? These 2 Winning Stocks Are Still Worth Buying. ↗

March 30, 2023

These two pharma stocks are rock-solid picks in any kind of market.

Via The Motley Fool

Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 27, 2023

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider.

Via Benzinga

Elon Musk-Led Neuralink Seeks Human Trial Collaborators, Credit Suisse May Face Disciplinary Action, First Citizens Takeover Silicon Valley Bank: Today's Top Stories ↗

March 27, 2023

Benzinga

Via Benzinga

Novartis Surges As It Goes After Eli Lilly's Second Biggest Moneymaker ↗

March 27, 2023

The battle in early-stage breast cancer is heating up as Novartis enters the ring.

Via Investor's Business Daily

Why Novartis Shares Are Trading Higher Premarket Today ↗

March 27, 2023

Novartis AG (NYSE: NVS) shares are trading higher in the premarket session after its breast cancer drug showed clinical benefit in early-stage breast cancer.

Via Benzinga

First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

March 27, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

2 Biotech Stocks That Could Make You Richer ↗

March 21, 2023

One is a well-established, large-cap drugmaker, while the other is still making a name for itself in the industry.

Via The Motley Fool

Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo ↗

March 20, 2023

Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days.

Via Benzinga

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

Headline News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today